Cystagon®
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 19 | ライソゾーム病 | 5 |
19. ライソゾーム病
臨床試験数 : 899 / 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
Showing 1 to 5 of 5 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01733316 (ClinicalTrials.gov) | January 31, 201320130131 | 16/11/201220121116 | Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsules (RP103) in Cystinosis Open-Label, Safety and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-Release Capsule ... | A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients With Cystinosis A Long-Term, Open-Label, Safety, Tolerability and Superior Effectiveness Study of Cysteamine Bitartr ... | Cystinosis | Drug: RP103;Drug: Cystagon® | Horizon Pharma USA, Inc. | NULL | Completed | 12 Years | N/A | All | 41 | Phase 3 | United States;Belgium;France;Italy;Netherlands;United Kingdom |
| 2 | EUCTR2009-017882-42-NL (EUCTR) | 19/10/201020101019 | 25/06/201020100625 | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | Cystinosis MedDRA version: 12.1;Level: LLT;Classification code 10011777;Term: Cystinosis | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate Product Code: RP103 INN or Proposed ... | Raptor Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | 20 | Netherlands;France | |||
| 3 | EUCTR2009-017882-42-FR (EUCTR) | 12/08/201020100812 | 14/06/201020100614 | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Efficacy of Cysteamine BitartrateDelayed-release Capsules (RP103), Compared to Cystagon® in Patientswith Nephropathic Cystinosis A Randomized, Crossover, Pharmacokinetic and PharmacodynamicStudy to Determine the Safety and Effica ... | Cystinosis MedDRA version: 12.1;Level: LLT;Classification code 10011777;Term: Cystinosis | Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Proposed INN: mercaptamine bitartrate INN or Proposed INN: mercaptamine bitartrate Trade Name: Cystagon Product Name: Cysteamine bitartrate (INN: mercaptamine bitartrate ) Product Code: RP103 INN or Propose ... | Raptor Therapeutics Inc. | NULL | Not Recruiting | Female: yes Male: yes | Phase 3 | France;Netherlands | |||
| 4 | NCT01000961 (ClinicalTrials.gov) | June 201020100600 | 22/10/200920091022 | Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon® in Patients With Cystinosis Phase 3 Study of Cysteamine Bitartrate Delayed-release (RP103) Compared to Cystagon®in Patients With ... | A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Efficacy of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cystagon® in Patients With Nephropathic Cystinosis A Randomized, Crossover Pharmacokinetic and Pharmacodynamic Study to Determine the Safety and Effica ... | Cystinosis | Drug: Cystagon® (Cysteamine Bitartrate);Drug: Cysteamine Bitartrate Delayed-release Capsules (RP103) | Horizon Pharma USA, Inc. | NULL | Completed | 6 Years | N/A | All | 43 | Phase 3 | United States;France;Netherlands |
| 5 | NCT00872729 (ClinicalTrials.gov) | May 200920090500 | 27/3/200920090327 | Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon® in Patients With Cystinosis Pilot Study of Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of RP103 Compared to Cystagon ... | A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate (Cystagon®) in Patients With Nephropathic Cystinosis A Pilot Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Cysteamin ... | Cystinosis | Drug: Cystagon®;Drug: RP103 | Horizon Pharma USA, Inc. | NULL | Completed | N/A | N/A | All | 9 | Phase 1/Phase 2 | United States |